Surgical and endovascular treatment of brain aneurysm

Series
Cerebral endovascular and surgical interventions
Status
Published
Date
Number of report
032

Ask the expert

(we accept only company emails)

Report presents summary of reimbursement situation for surgical and endovascular brain aneurysm treatments in European countries. Day case admissions are not considered in the report.  

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

The report includes the following procedures:

  • Surgical clipping
  • Endovascular placement of a flow diversion device
  • Intra-saccular flow diversion
  • Endovascular coiling
  • Stent-assisted coiling

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

The only reimbursement within public / statutory health insurance systems is considered.

Manufacturers of devices for brain aneurysm treatment include:

Flow diversion device

  • Acandis GmbH (DERIVO Embolisation Device)
  • Balt Extrusion (The SILK flow diverter)
  • Medtronic (Pipeline Flex Embolization Device)
  • MicroPort NeuroTech (Tubridge Vascular Reconstruction Device)
  • MicroVention (Flow-Redirection Endoluminal Device)
  • MINT Technologies (Sphere)
  • Phenox GmbH (p64 Flow Modulation Device)
  • Stryker Neurovascular (Surpass Streamline Flow Diverter)

Coils for intracranial aneurysms

  • Cerenovus (Galaxy g3 MINI Coil)
  • Codman Neuro (Orbit galaxy, Micrusphere, Cashmere, Deltamaxx)
  • Penumbra Inc (Penumbra SMART COIL, Penumbra Coil 400)
  • Stryker (Target 360, Target Ultrasoft)
  • Taewoong Medical Co. (K3 Platinum Coil)
  • Terumo (Hydrogel coating embolization coil azur cx)

Stent-assisted coiling

  • Acandis GmbH (ACCLINO flex plus Stent)
  • Medtronic (Axium Detachable Coils, Solitaire Platinum Revascularization Device)
  • Microvention (LVIS, LVIS Jr. devices)
  • Stryker (Intracranial stent / nitinol / self-expanding / embolization coil support Neuroform EZ)
  • Taewoong Medical Co. (Barricade Coil System

Table of content
 
1.    Introduction and summary
2.    Contents
3.    Executive summary table
4.    Methodology
5.    What’s new
6.    Reimbursement analysis in Austria

6.1.    Overview of the reimbursement system
6.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
6.2.1.    Procedure coding
6.2.2.    Diagnosis coding
6.2.3.    Payment mechanism and reimbursement tariffs
6.2.4.    Policy considerations
7.    Reimbursement analysis in Belgium
7.1.    Overview of the reimbursement system
7.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
7.2.1.    Procedure coding
7.2.2.    Material coding
7.2.3.    Payment mechanism and reimbursement tariffs
7.2.4.    Policy considerations
7.2.5.    Procedure volume information
8.    Reimbursement analysis in Denmark
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
8.2.1.    Procedure coding 
8.2.2.    Diagnosis coding
8.2.3.    Payment mechanism and reimbursement tariffs
8.2.4.    Policy considerations
8.2.5.    Procedure volume information
9.    Reimbursement analysis in England
9.1.    Overview of the reimbursement system
9.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
9.2.1.    Procedure coding 
9.2.2.    Diagnosis coding
9.2.3.    Payment mechanism and reimbursement tariffs
9.2.4.    Policy considerations 
9.2.4.1.    Specifics of commissioning of the procedure
9.2.4.2.    Health technology assessments by NICE
9.2.5.    Procedure volume information
10.    Reimbursement analysis in France
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
10.2.1.    Procedure coding 
10.2.2.    Diagnosis coding
10.2.3.    Payment mechanism and reimbursement tariffs
10.2.4.    Policy considerations by HAS
10.2.5.    Procedure volume information
11.    Reimbursement analysis in Germany
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
11.2.1.    Procedure coding 
11.2.2.    Diagnosis coding
11.2.3.    Payment mechanism and reimbursement tariffs
11.2.4.    Policy considerations by G-BA
11.2.5.    Procedure volume information
12.    Reimbursement analysis in Italy
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
12.2.1.    Procedure coding
12.2.2.    Diagnosis coding
12.2.3.    Payment mechanism and reimbursement tariffs
12.2.4.    Policy considerations
12.2.5.    Procedure volume information
13.    Reimbursement analysis in the Netherlands
13.1.    Overview of the reimbursement system
13.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
13.2.1.    Procedure coding 
13.2.2.    Material codes
13.2.3.    Diagnosis coding
13.2.4.    Payment mechanism and reimbursement tariffs
13.2.5.    Policy considerations
13.2.6.    Procedure volume information
14.    Reimbursement analysis in Norway
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
14.2.1.    Procedure coding 
14.2.2.    Diagnosis coding
14.2.3.    Payment mechanism and reimbursement tariffs
14.2.4.    Policy considerations 
14.2.5.    Procedure volume information
15.    Reimbursement analysis in Sweden
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm 
15.2.1.    Procedure coding 
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs
15.2.4.    Policy considerations 
15.2.5.    Procedure volume information
16.    Reimbursement analysis in Switzerland
16.1.    Overview of the reimbursement system
16.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
16.2.1.    Procedure coding 
16.2.2.    Diagnosis coding
16.2.3.    Payment mechanism and reimbursement tariffs
16.2.4.    Policy considerations
16.2.5.    Procedure volume information
17.    Disclaimer

17

Jun 2022

On May 31, 2022, it was announced by the Ministry of Health that the Council of Ministers authorized the distribution of almost €400 million for the renovation of high-tech equipment in the National Health System (SNS) through the High-End Technology Equipment Investment Plan (INVEAT) of the SNS.

Read more

01

Jun 2022

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in May 2022. Thirty-one recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular and peripheral vascular, diagnostic imaging, interventional radiology, orthopedic, neurovascular and neuromodulation, endocrine and E-health devices, as well as medical aids.

Read more

31

May 2022

In May 2022, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (endoanchoring systems in endovascular aortic aneurysm repair, supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis, personalized external aortic root support using mesh in people with Marfan syndrome), one Medical Technologies Guidance (Sleepio to treat insomnia and insomnia symptoms), and six Medtech innovation Briefings (ViewSite Brain Access System, Granulox for managing chronic wounds, AMBLor for identifying melanomas, Bladder EpiCheck for detecting bladder cancer recurrence, and others). No MedTech-related clinical guidelines were published.

Read more

16

May 2022

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in April 2022. Thirty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, orthopedic, neurovascular, and neuromodulation and other devices, as well as medical aids.

Read more

15

Apr 2022

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in March 2022. More than 15 recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, orthopedic, and neurovascular devices, as well as medical aids.

Read more
(we accept only company emails)